Drug delivery systems for intraperitoneal therapy

Pharmaceutical Research

Volumn 27, Issue 5, 2010, Pages 735-738

  Bajaj, Gaurav ^a   Yeo, Yoon ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Hydrogels; Intraperitoneal drug delivery; Intraperitoneal malignancies; Micro nanoparticles; Peritoneal adhesion

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CASTOR OIL; CISPLATIN; CREMOPHOR; DIPHTHERIA TOXIN; DNA; DOCETAXEL; DRUG CARRIER; LIPOSOME; NANOPARTICLE; PACLITAXEL; PLATINUM COMPLEX; POLY(BETA AMINO ESTER); POLYGLACTIN; POLYMER; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; BIOCOMPATIBILITY; CANCER RECURRENCE; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLLOID; CYTOREDUCTIVE SURGERY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TARGETING; GYNECOLOGIC SURGERY; HUMAN; HYDROGEL; INTRAPERITONEAL DRUG ADMINISTRATION; MICELLE; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; NOTE; OVARY CANCER; PERITONEAL CAVITY; PERITONEAL DISEASE; PERITONEUM ADHESION; PERITONEUM CANCER; PERITONEUM TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAPERITONEAL; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; TISSUE ADHESIONS;

EID: 77953289893     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0031-z     Document Type: Note

References (47)

1. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg. 2001;18:260-273
2. Tingstedt B, Andersson E, Isaksson K, Andersson R. Clinical impact of abdominal adhesions: what is the magnitude of the problem? Scand J Gastroenterol. 2008;43:255-261
3. Davies JM, O'Neil B. Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options. Expert Opin Investig Drugs. 2009;18:913-919
4. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer 2000;88:358-363
5. Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Muller JM, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE. 2009;4:e571.5.
6. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398-403. (Pubitemid 32494653)
7. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9-12. (Pubitemid 27026949)
8. DiZerega GS. Use of adhesion prevention barriers in pelvic reconstructive and gynecologic surgery. In: diZerega GS, editor. Peritoneal surgery. New York: Springer; 2000.
9. Yeo Y, Kohane DS. Polymers in the prevention of peritoneal adhesions. Eur J Pharm Biopharm. 2008;68:57-66.
10. Yeo Y, Adil M, Bellas E, Astashkina A, Chaudhary N, Kohane DS. Prevention of peritoneal adhesions with an in situ crosslinkable hyaluronan hydrogel delivering budesonide. J Control Release. 2007;120:178-235
11. Yeo Y, Bellas E, Highley CB, Langer R, Kohane DS. Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model. Biomaterials 2007;28:3704-3713
12. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955
13. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
14. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200 (Pubitemid 46606249)
15. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43. (Pubitemid 43048949)
16. Gadducci A, Camino F, Chiara S, Brunetu I, Tanganelli L, Romanini A, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico NordOvest. Gynecol Oncol. 2000;76:157-162
17. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007
18. Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, et al. A comparative study of intraperitoneal, carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56:291-296
19. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage HI optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet. 2001;72:55-60.
20. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related, to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5.
21. Gonzalez-Moreno S, Ortega-Perez G, Gonzalez-Bayon L. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Oncol. 2009;100:287-292
22. Nissan A, Stojadinovic A, Garofalo A, Esquivei J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present, and future. J Surg Oncol. 2009;100:335-344
23. Dedrick RL, Myers CE, Bungay PM, DeVita Jr VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1-11.
24. Markman. M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001;61:1057-1065
25. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis Jr JL, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10:148591. (Pubitemid 23059933)
26. NCI clinical announcement for Intraperitoneal chemotherapy for ovarian cancer http://ctep.cancer.gov/highlights/docs/clin-annc010506.pdf.
27. Poveda AA, Salazar RR, del Campo JJM, Mendiola CC, Cassinello JJ, Ojeda BB, et al. Update in the management of ovarian and cervical carcinoma. Clin Transi Oncol. 2007;9:44351.
28. Hirano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci. 1985;74:915-921 (Pubitemid 15014130)
29. Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther. 1971;178:562-564
30. Mohamed. F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405-410
31. Mohamed F, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions. J Surg Res. 2003;113:114-120 (Pubitemid 36999800)
32. Tsai M, Lu Z, Wang J, Yeh T-K, Wientjes M, Au J. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res. 2007;24:1691-1701 (Pubitemid 47206619)
33. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumorpenetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008;327:673-752
34. Yeo Y, Ito T, Bellas E, Highley CB, Marini R, Kohane DS. In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. Ann Surg. 2007;245:819-824
35. Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002;8: 1237-1241 (Pubitemid 35177380)
36. Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol. 1999;44:241-248 (Pubitemid 29350180)
37. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-1268
38. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mateři Res Part A. 2006;77A:351-361 (Pubitemid 47233537)
39. Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A, Horikiri Y, et al. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm. 2002;54:1-7. (Pubitemid 34663850)
40. Huang YH, Zugates GT, Peng W, Holtz D, Dunton C, Green JJ, et al. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 2009;69: 6184-6191
41. Fukumura D, Jain RK. Tumor microvasculature and. microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74:72-84. (Pubitemid 350051025)
42. Jain RK. Delivery of molecular and cellular medicine to solid, tumors. Adv Drug Deliv Rev. 2001;46:149-168
43. Bennis S, Chapey C, Robert J, Couvreur P. Enhanced cytotoxicity of doxorubicin encapsulated, in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer. 1994;30:89-93. (Pubitemid 24058096)
44. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 2000;6:1949-1957
45. Michieli M, Damiani D, Ermacora A, Masolini P, Michelutti A, Michelutti T, et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol. 1999;106:92-99 (Pubitemid 29343532)
46. Rahman A, Husain SR, Siddiqui J, Verma M, Agresti M, Center M, et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst. 1992;84: 1909-1915 (Pubitemid 23004619)
47. Sadava D, Coleman A, Kane SF. Liposomal daunorubicin. overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res. 2002;12:301-309 (Pubitemid 36008393)